Trending NewsTrending NewsNASDAQ:PRCT PROCEPT BioRobotics (PRCT) Stock Price, News & Analysis $19.47 +0.03 (+0.15%) Closing price 09/17/2026 04:00 PM EasternExtended Trading$19.46 0.00 (-0.03%) As of 09/17/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About PROCEPT BioRobotics Stock (NASDAQ:PRCT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get PROCEPT BioRobotics alerts:Sign Up Key Stats Today's Range$19.04▼$19.5850-Day Range$16.69▼$22.8952-Week Range$16.67▼$39.99Volume850,008 shsAverage Volume1.09 million shsMarket Capitalization$1.12 billionP/E RatioN/ADividend YieldN/APrice Target$25.09Consensus RatingHold Company Overview PROCEPT BioRobotics Corporation is a medical technology company focused on developing and commercializing robotic solutions for urologic care. The company’s primary focus is the treatment of benign prostatic hyperplasia (BPH), a noncancerous enlargement of the prostate that can cause urinary symptoms. Its flagship product is the AQUABEAM Robotic System, which uses image guidance, robotics, and high-velocity waterjet technology to remove targeted prostate tissue without the use of a traditional cutting instrument. The system is designed to provide a standardized, tissue-sparing approach to prostate resection and is used in hospitals and urology practices. Founded in 2007 and headquartered in Redwood City, California, PROCEPT BioRobotics markets its technology in the United States and internationally through a combination of direct commercial operations and distribution partners. The company is led by President and Chief Executive Officer Reza Zadno.AI Generated. May Contain Errors. Read More PROCEPT BioRobotics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks82nd Percentile Overall ScorePRCT MarketRank™: PROCEPT BioRobotics scored higher than 82% of companies evaluated by MarketBeat, and ranked 103rd out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingHold Consensus RatingPROCEPT BioRobotics has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on 1 strong buy rating, 3 buy ratings, 9 hold ratings, and 2 sell ratings.Upside PotentialPROCEPT BioRobotics has a consensus price target of $25.09, representing about 28.9% upside from its current price of $19.47.Amount of Analyst CoveragePROCEPT BioRobotics has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about PROCEPT BioRobotics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for PROCEPT BioRobotics are expected to grow in the coming year, from ($1.67) to ($1.07) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of PROCEPT BioRobotics is -10.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of PROCEPT BioRobotics is -10.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPROCEPT BioRobotics has a P/B Ratio of 2.97. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about PROCEPT BioRobotics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted13.18% of the float of PROCEPT BioRobotics has been sold short.Short Interest Ratio / Days to CoverPROCEPT BioRobotics has a short interest ratio ("days to cover") of 8.56.Change versus previous monthShort interest in PROCEPT BioRobotics has recently decreased by 5.92%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPROCEPT BioRobotics does not currently pay a dividend.Dividend GrowthPROCEPT BioRobotics does not have a long track record of dividend growth. News and Social Media3.2 / 5News Sentiment0.08 News SentimentPROCEPT BioRobotics has a news sentiment score of 0.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 30 news articles for PROCEPT BioRobotics this week, compared to 9 articles on an average week.Search Interest3 people have searched for PRCT on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows3 people have added PROCEPT BioRobotics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership3.7 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $476,464.00 in company stock, which represents 0.0427% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, PROCEPT BioRobotics insiders have bought 2,180.51% more of their company's stock than they have sold. Specifically, they have bought $498,315.00 in company stock and sold $21,851.00 in company stock.Percentage Held by Insiders4.00% of the stock of PROCEPT BioRobotics is held by insiders.Percentage Held by Institutions89.46% of the stock of PROCEPT BioRobotics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about PROCEPT BioRobotics' insider trading history. Receive PRCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PROCEPT BioRobotics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PRCT Stock News HeadlinesPRCT ALERT: Hagens Berman Reminds PROCEPT BioRobotics (PRCT) Investors of the September 22, 2026 Lead Plaintiff DeadlineSeptember 17 at 12:22 PM | tmcnet.comPROCEPT BioRobotics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against PROCEPT BioRobotics Corporation - PRCTSeptember 17 at 11:53 AM | globenewswire.comThe cat is out the bagAlmost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered separation packages to 8,500 workers, and Oracle is reportedly eliminating up to 30,000 positions. Goldman Sachs estimates 12,400 Americans are being financially displaced every single day. Analyst Porter Stansberry says the real driver runs deeper than AI - and two Nobel Prize winners have issued the same warning. He calls it the Final Displacement, and he's releasing a full investigation with specific companies to buy and sell before the next wave hits. | Porter & Company (Ad)SueWallSt Reminds PROCEPT BIOROBOTICS CORPORATION Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 22, 2026 - PRCTSeptember 17 at 10:07 AM | prnewswire.comPRCT Investors Have Opportunity to Lead PROCEPT BioRobotics Corporation Securities Fraud Lawsuit with SBS LawSeptember 17 at 10:00 AM | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in PROCEPT BioRobotics Corporation of Class Action Lawsuit and Upcoming Deadlines - PRCTSeptember 17 at 10:00 AM | prnewswire.comSHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against PROCEPT BioRobotics Corporation (PRCT)September 17 at 8:17 AM | globenewswire.comPRCT 6-DAY DEADLINE ALERT: PROCEPT BioRobotics Corporation Investors Alerted to September 22, 2026 Lead Plaintiff Deadline in Class Action LawsuitSeptember 16 at 5:00 PM | globenewswire.comSee More Headlines PRCT Stock Analysis - Frequently Asked Questions How have PRCT shares performed this year? PROCEPT BioRobotics' stock was trading at $31.46 at the beginning of 2026. Since then, PRCT shares have decreased by 38.1% and is now trading at $19.47. How were PROCEPT BioRobotics' earnings last quarter? PROCEPT BioRobotics Corporation (NASDAQ:PRCT) posted its quarterly earnings data on Tuesday, August, 4th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by $0.01. PROCEPT BioRobotics's revenue for the quarter was up 19.3% on a year-over-year basis. Read the conference call transcript. When did PROCEPT BioRobotics IPO? PROCEPT BioRobotics (PRCT) raised $151 million in an IPO on Tuesday, September 14th 2021. The company issued 6,556,000 shares at $22.00-$24.00 per share. Who are PROCEPT BioRobotics' major shareholders? PROCEPT BioRobotics' top institutional shareholders include BlackRock Inc. (8.56%), Wellington Management Group LLP (2.22%), Jupiter Topco LLC (1.93%) and William Blair Investment Management LLC (1.24%). Insiders that own company stock include Frederic H Moll, Antal Rohit Desai, Kevin Waters, Reza Zadno, Alaleh Nouri, Morgan Colby Wood, Barry L Templin, Hisham Shiblaq and Larry L Wood. View institutional ownership trends. How do I buy shares of PROCEPT BioRobotics? Shares of PRCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of PROCEPT BioRobotics own? Based on aggregate information from My MarketBeat watchlists, some other companies that PROCEPT BioRobotics investors own include Invesco QQQ (QQQ), SPDR S&P 500 ETF Trust (SPY), Netflix (NFLX), Tesla (TSLA), NVIDIA (NVDA), SPDR Dow Jones Industrial Average ETF Trust (DIA) and Meta Platforms (META). Company Calendar Last Earnings8/04/2026Today9/17/2026Next Earnings (Estimated)11/03/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (17m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 PRCT's financial health is in the Red zone, according to TradeSmith. PRCT has been in this zone for over 17 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Equipment Current SymbolNASDAQ:PRCT CIK1588978 Webwww.procept-biorobotics.com Phone650-232-7200FaxN/AEmployees888Year Founded2009Price Target and Rating Average Price Target for PROCEPT BioRobotics$25.09 High Price Target$51.00 Low Price Target$19.00 Potential Upside/Downside+28.9%Consensus RatingHold Rating Score (0-4)2.20 Research Coverage15 Analysts Profitability EPS (Trailing Twelve Months)($1.94) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$95.57 million Net Margins-32.53% Pretax Margin-32.49% Return on Equity-30.62% Return on Assets-22.10% Debt Debt-to-Equity Ratio0.15 Current Ratio6.55 Quick Ratio5.35 Sales & Book Value Annual Sales$308.05 million Price / Sales3.62 Cash FlowN/A Price / Cash FlowN/A Book Value$6.55 per share Price / Book2.97Miscellaneous Outstanding Shares57,270,000Free Float54,983,000Market Cap$1.12 billion OptionableOptionable Beta0.91 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:PRCT) was last updated on 9/18/2026 by MarketBeat.com Staff. From Our PartnersIran War: Why Is Trump Protecting THEM?A powerful Middle Eastern government is reportedly seeking US intelligence, targeting help, and military prote...Banyan Hill Publishing | SponsoredMusk says UBI is coming. I say it's already here.Elon Musk says AI could make money irrelevant by 2036. One income program already exists today, funded not by ...Freedom Financial | SponsoredElon Musk’s Hushed FCC Filing. Sept 25th.Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the lar...Paradigm Press | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | Sponsored“This is the Perfect Tech Stock”Jeff Brown, the tech investor who identified Nvidia in 2016 before its 37,000% run, has flagged a new AI compa...Brownstone Research | SponsoredThe dollar reset no one told you aboutPorter Stansberry says a dollar reset is underway - one that has happened only once before in America's 250-ye...Porter & Company | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PROCEPT BioRobotics Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share PROCEPT BioRobotics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
